|
Online Database of Chemicals from Around the World | Search | Submit | Advertise | |
Home >> Chemical Listing >> Laronidase>> Market Analysis Reports |
Market Analysis Reports of Laronidase |
|
Lamotrigine (CAS 210589-09-6) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Enzyme Replacement Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Products (Galsulfase, Velaglucerase Alfa, Laronidase, Asfotasealfa, Others), By Diseases (Exocrine Pancreatic Insufficiency (EPI), Pompe Disease, Scheie Syndrome, Maroteaux-Lamy Syndrome, Gaucher Disease, Others), By Route of Administrations (Oral, Parenteral, Others), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Region and Competition, 2020-2030F ... such as Velaglucerase Alfa, Galsulfase, and Laronidase requiring this method. IV administration ensures ... Market, By Products: Galsulfase Velaglucerase Alfa Laronidase Asfotasealfa Others Enzyme Replacement Therapy ... Enzyme Replacement Therapy Market Size, Trends, Analysis, and Outlook By Product (Agalsidase Beta, Imiglucerase , Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others), By Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), By End-User (Hospitals, Infusion Centers & Home Healthcare Setting), by Region, Country, Segment, and Companies, 2024-2030 ... , Imiglucerase , Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others), By Disease (Gaucher Disease, Fabry ... Imiglucerase Velaglucerase Alfa Idursulfase Galsulfase Laronidase Others By Disease Gaucher Disease Fabry ... Global Enzyme Replacement Therapy Market Size study & Forecast, by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others) by Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), by End User (Hospitals, Infusion Centers & Home Healthcare Setting) and Regional Analysis, 2022-2029 ... Imiglucerase Velaglucerase Alfa Idursulfase Galsulfase Laronidase Others By Disease: Gaucher Disease Fabry ... BioMarin Pharmaceutical Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... ), Kuvan (sapropterin dihydrochloride) tablets, Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The ... Genzyme Corp. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... of the enzyme alfa-glucosidase. Aldurazyme (laronidase): The company formed a joint venture ... Lysosomal Storage Disease Treatment Market Size, Trends, Analysis, and Outlook By Therapy (Enzyme Replacement Therapy, Substrate Reduction Therapy), By Application (Gaucher disease, Cystinosis, Pompe Disease, Fabry Disease, Others), by Country, Segment, and Companies, 2024-2032 ... Alfa -Taliglucerase Alfa -Agalsidase beta -Laronidase -Imiglucerase -Others Substrate Reduction Therapy ... Mucopolysaccharidoses Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 ... enzyme replacement therapies (ERTs) like laronidase, idursulfase, elosulfase alfa, etc., which ... Enzyme Replacement Therapy Market Size, Share & Trends Analysis Report By Product (Imiglucerase), By Therapeutic Condition (MPS), By Route Of Administration (Oral), By End-use, By Region, And Segment Forecasts, 2025 - 2030 This report can be delivered to the clients within 3 Business Days Enzyme Replacement Therapy Market Growth & Trends The global enzyme replacement therapy market size is estimated treach USD 17.26 billion by 2030, registering tgrow at a CAGR of 9.0% from ... Enzyme Replacement Therapy Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type ... SCID. Trends highlight niche applications. Laronidase: Expected growth of 6.0%-10.0%, for MPS I. Advances ... for MPS disorders. Takeda: Provides laronidase for MPS I. Amicus Therapeutics: Focuses ... Enzyme Replacement Therapy (ERT) Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application ... alfa), NAGLAZYME (galsulfase), and ALDURAZYME (laronidase), tallying 1.3 to 1.5 billion USD in 2024, leveraging ... stewards Fabrazyme (agalsidase beta), ALDURAZYME (laronidase), Cerezyme (imiglucerase), and Lumizyme/Myozyme ... Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H1 2018 Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H1 2018 SUMMARY According to the recently published report 'Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H1 2018'; Alpha L-Iduronidase (IDUA or EC 3.2.1.76) pipeline Target ... Alpha L-Iduronidase - Pipeline Review, H1 2020 Alpha L-Iduronidase - Pipeline Review, H1 2020 SUMMARY Alpha L-Iduronidase (IDUA or EC 3.2.1.76) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/ ... Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Drugs In Development, 2021 Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Drugs In Development, 2021 SUMMARY Alpha L-Iduronidase (IDUA or EC 3.2.1.76) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by ... Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY According to the recently published report 'Alpha L-Iduronidase - Drugs In Development, 2022'; ... Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis ... 3D Printing Medical Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (3 D Printer, 3 D Bioprinter, Material, Software, Services), By Application (Surgical Guides, Prosthetics, Implants), By Region and Competition, 2020-2030F ... Market, By Component: Galsulfase Velaglucerase Alfa Laronidase Asfotasealfa Others 3D Printing Medical Devices ... Mucopolysaccharidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The mucopolysaccharidosis market has been comprehensively analyzed in IMARC's new report titled "Mucopolysaccharidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mucopolysaccharidosis (MPS) refers to ... |